Aratana Therapeutics (NASDAQ:PETX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
PETX has been the topic of a number of other reports. Jefferies Group set a $9.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 16th. ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. CL King initiated coverage on shares of Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating on the stock. HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research note on Friday, November 17th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a research note on Monday, December 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Aratana Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.55.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. During the same period last year, the company posted ($0.38) EPS. The business’s revenue was up 1440.0% on a year-over-year basis. equities analysts anticipate that Aratana Therapeutics will post -1.03 EPS for the current fiscal year.
In other news, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of Aratana Therapeutics stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $6.53, for a total transaction of $760,849.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Peter Steven St sold 50,000 shares of Aratana Therapeutics stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $7.00, for a total transaction of $350,000.00. Following the sale, the insider now directly owns 529,359 shares in the company, valued at approximately $3,705,513. The disclosure for this sale can be found here. Insiders sold a total of 1,087,032 shares of company stock worth $6,344,891 over the last three months. Corporate insiders own 5.20% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in PETX. Financial Counselors Inc. purchased a new stake in shares of Aratana Therapeutics during the 1st quarter valued at approximately $101,000. American International Group Inc. increased its holdings in Aratana Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,354 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Aratana Therapeutics by 7.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,200 shares during the last quarter. Ray Gerald L & Associates Ltd. increased its holdings in Aratana Therapeutics by 38.2% in the 1st quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 6,600 shares during the last quarter. Finally, A.R.T. Advisors LLC increased its holdings in Aratana Therapeutics by 19.3% in the 4th quarter. A.R.T. Advisors LLC now owns 17,900 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 2,900 shares during the last quarter. 73.76% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/17/aratana-therapeutics-petx-lowered-to-sell-at-zacks-investment-research.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.